Gemtesa 75 MG tablet 90S
Ended Awarded
- Contract number
- SPE2DR26FSUU3
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,300
Award facts
- Contract value 100% obligated
- $4,299.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $4,299.80 on November 12, 2025, for the supply of Gemtesa 75 mg tablets (90-count packaging), with an ultimate completion date of November 13, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor and healthcare solutions provider that serves as a critical federal medical procurement vendor, particularly for military and veteran healthcare systems. The company's DLA IDC encompasses a broad range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. Through its federal contract awards, AmerisourceBergen consistently demonstrates the capability to meet DLA procurement requirements for pharmaceutical commodities supporting Defense Health Agency operations and other government healthcare systems. The current delivery order for Gemtesa, a medication used in treating overactive bladder, exemplifies the company's role in supplying specialized pharmaceutical products to federal military healthcare programs.
Quick answers
Who was awarded contract SPE2DR26FSUU3?
SPE2DR26FSUU3 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on November 12, 2025.
How much is contract SPE2DR26FSUU3 worth?
The government has obligated $4,300 on SPE2DR26FSUU3.
Is contract SPE2DR26FSUU3 an order under another contract?
Yes. SPE2DR26FSUU3 is a delivery order under SPE2DR25D1004, an indefinite delivery contract.
Was contract SPE2DR26FSUU3 competed?
The extent of competition for SPE2DR26FSUU3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award